Imfinzi approved in EU for early gastric cancer

AstraZeneca PLC (LSE: AZN) has announced the European Union's approval of its immunotherapy drug, Imfinzi, for the treatment of early gastric and gastroesophageal junction (GEJ) cancers. This marks a significant milestone as Imfinzi, in combination with FLOT chemotherapy, becomes the first and only perioperative immunotherapy approved for these conditions. The approval is based on the results of the MATTERHORN Phase III trial, which demonstrated a statistically significant 22% reduction in the risk of death compared to chemotherapy alone, with an estimated 69% of patients alive at three years. Furthermore, the trial revealed a 29% reduction in the risk of disease progression, recurrence, or death, with event-free survival rates of 67.4% at 24 months for the Imfinzi arm versus 58.5% for the comparator group.

The MATTERHORN trial involved 948 patients who were randomized to receive either Imfinzi plus FLOT chemotherapy or placebo plus FLOT chemotherapy. The treatment regimen consists of two cycles of Imfinzi in conjunction with chemotherapy before and after surgery, followed by Imfinzi monotherapy. The trial's primary endpoint was event-free survival (EFS), which is defined as the time from randomization until the occurrence of disease progression, recurrence, or death. The results indicate that the Imfinzi-based regimen not only improves survival rates but also establishes a new standard of care for patients with resectable early-stage gastric and GEJ cancers, which are known for their high recurrence rates despite curative-intent surgery.

AstraZeneca's current market capitalisation stands at approximately £150 billion, reflecting its position as a leading player in the biopharmaceutical sector. The approval of Imfinzi is expected to enhance the company's revenue streams, particularly in the oncology segment, which has been a focus area for AstraZeneca. The company has a robust cash position, with cash reserves reported at £8 billion, which should provide a solid foundation for ongoing research and development initiatives. Given the approval's timing and the potential market size—approximately 15,500 drug-treated patients in the EU with early-stage gastric or GEJ cancer—AstraZeneca is well-positioned to capture significant market share.

In terms of valuation, AstraZeneca's enterprise value is reflective of its strong pipeline and market presence. The approval of Imfinzi is expected to bolster the company's growth trajectory, particularly as it has already received similar approvals in the US and other countries. Comparatively, other companies in the oncology space, such as GSK (LSE: GSK) and Novartis (NYSE: NVS), are also focused on innovative cancer therapies, but AstraZeneca's unique position with Imfinzi as a perioperative treatment differentiates it from its peers. GSK, for instance, has a market cap of approximately £80 billion and is also engaged in oncology, but lacks a direct competitor to Imfinzi in this specific treatment setting.

The funding sufficiency for AstraZeneca appears robust, with the company having sufficient cash reserves to support its ongoing clinical trials and commercialisation efforts for Imfinzi. The approval is not expected to trigger immediate dilution risks, as AstraZeneca has not indicated any plans for new equity financing in the near term. However, the company must remain vigilant regarding the competitive landscape and potential future funding requirements as it continues to expand its oncology portfolio.

Despite the positive news surrounding Imfinzi, there are inherent risks associated with the approval and subsequent market launch. One specific risk is the potential for competition from other emerging therapies targeting gastric and GEJ cancers. As the oncology landscape evolves, AstraZeneca must ensure that it maintains a competitive edge through continuous innovation and effective marketing strategies. Additionally, the long-term safety and efficacy of Imfinzi will need to be closely monitored as it is rolled out in clinical settings, given that the safety profile was consistent with known profiles but still presents a risk of adverse events.

Looking ahead, the next measurable catalyst for AstraZeneca will be the anticipated regulatory applications for Imfinzi in Japan and other countries, which are currently under review. The timeline for these approvals is not explicitly stated, but given the momentum from the EU approval, it is reasonable to expect updates within the next 12 months. The successful launch of Imfinzi in these additional markets could further solidify AstraZeneca's position in the oncology sector and enhance its revenue potential.

In conclusion, the approval of Imfinzi for early gastric and GEJ cancers represents a significant advancement in treatment options for patients and positions AstraZeneca favorably within the oncology market. This announcement is classified as significant due to its potential to materially impact the company's valuation and market presence. The approval not only establishes a new standard of care but also reinforces AstraZeneca's commitment to improving patient outcomes in oncology, making it a pivotal moment in the company's ongoing strategy.

Key insights

• ●Imfinzi shows 22% reduction in death risk.
• ●69% of patients alive at three years.
• ●Approval sets a new standard of care.

Disagree with this article?